Skye Bioscience, Inc.

EMBI

US83086J2006

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 01/06/2024 am IST			5-day change	1st Jan Change
11.61 ^USD	-0.34%		-3.73%	+326.84%

10/05	Skye Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
23/04	Skye Bioscience, Inc.(NasdaqGM:SKYE) added to NASDAQ Transportation Index	CI

Skye Bioscience, Inc. Appoints Rai as Member of the Nominating and Corporate Governance Committee of the Board

January 07, 2023 at 03:28 am IST

Skye Bioscience, Inc. announced that on January 5, 2023, the Board of Directors of the Company appointed Mr. Rai as a member of the Nominating and Corporate Governance Committee of the Board.

Latest news about Skye Bioscience, Inc.

Skye Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	11/05	CI
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to NASDAQ Transportation Index	23/04	CI
Skye Bioscience, Inc.(NasdaqGM:SKYE) added to NASDAQ Composite Index	12/04	CI
Skye Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03	CI
Piper Sandler Adjusts Skye Bioscience Price Target to $20 From $12, Maintains Overweight Rating	14/03	MT
Skye Bioscience, Inc. announced that it has received $40 million in funding	13/03	CI
Skye Bioscience, Inc. announced that it expects to receive $40 million in funding	11/03	CI
Skye Bioscience Announces Board Changes	04/03	CI
Skye Bioscience Completes Enrollment of Phase 2A Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension	26/02	CI
Skye Bioscience, Inc. announced that it has received $49.99101 million in funding	12/02	CI
Skye Bioscience, Inc. announced that it expects to receive $50.249992 million in funding	29/01	CI
Skye Bioscience, Inc. Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab	11/12	CI
Skye Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Skye Bioscience, Inc. Announces Board Appointments	01/23/01	CI
Skye Bioscience, Inc. acquired Bird Rock Bio, Inc. for $15.6 million.	21/23/21	CI
Skye Bioscience, Inc. announced that it has received $12 million in funding	18/23/18	CI
Skye Bioscience, Inc. announced that it expects to receive $12 million in funding	15/23/15	CI
Skye Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/23/08	CI
Skye Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Skye Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	01/23/01	CI
Skye Bioscience, Inc. Auditor Raises 'Going Concern' Doubt	31/23/31	CI
Skye Bioscience, Inc. Announces Board Changes	28/23/28	CI
Skye Bioscience, Inc. Announces Resignation of Bobby Rai as a Member of the Board of Directors and the Nominating and Corporate Governance Committee of the Board	22/23/22	CI
Skye Bioscience, Inc. Appoints Deborah Charych to Board of Directors	16/23/16	CI
Skye Bioscience Announces First-in-Human Phase 1 Trial of Proprietary Cannabinoid Derivative and Nanoemulsion Formulation Designed to Potentially Treat Glaucoma	24/23/24	CI

Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system. The Company's clinical assets focus on the modulation of cannabinoid receptor 1 (CB1) to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. Its Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion (SBI-100 OE), a CB1 agonist (activator), being developed for the treatment of glaucoma and ocular hypertension. The Company's Phase 2 study in obesity is designed to evaluate nimacimab's weight loss potential either as a single agent or in combination with a glucagon-like peptide-1 (GLP-1) agonist like semaglutide.

Sector

Biotechnology & Medical Research

Calendar

05/06/2024 - Jefferies Global Healthcare Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.61 USD

Average target price

22 USD

Spread / Average Target

+89.49%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SKYE BIOSCIENCE, INC.	+326.84%	326M
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
BIO-TECHNE CORPORATION	+0.04%	12.16B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research